Business Standard

Amidst controversy, Indian companies continue to manufacture HCQ

Once touted as a 'wonder drug', HCQ has been battling global controversies around its safety and efficacy as a prophylactic against the new coronavirus SARS-CoV-2.

hydroxychloroquine, hcq, drugs, coronavirus, pharma
Premium

The inexpensive drug that has anti-inflammatory effects (the reason it is used in arthritis) came into limelight after US President Donald Trump promoted it. Industry insiders feel that this well may have also been the drug's undoing.

Sohini Das Mumbai
Amidst a raging global controversy, hydroxychloroquine (HCQ) makers in India continue to produce the drug for regular rheumatoid arthritis and diabetes patients apart from catering to export orders. India is the world's largest manufacturer of HCQ, which is also an anti-malaria drug. 

The once touted “wonder drug” has been battling global controversies around its safety and efficacy as a prophylactic against Covid-19. India continues to use the drug as a preventive for frontline workers like health care professionals and police personnel, apart from high-risk individuals, like close contacts of Covid-19 patients. 

A source in one of India’s leading HCQ manufacturing

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in